Videos

Deepu Madduri, MD, assistant professor, medicine, hematology and medical oncology, Mount Sinai Hospital, discusses the results of the phase Ib/II CARTITUDE-1 trial of the BCMA-directed CAR T-cell therapy JNJ-4528 in patients with heavily pretreated relapsed/refractory multiple myeloma.

Reimbursement for CAR-T therapy has progressed to where commercially insured patients obtain coverage regularly, but issues remain for patients with Medicare, said John Sweetenham, MD, professor in the Department of Internal Medicine at UT Southwestern Medical Center and the Associate Director for Clinical Affairs at UTSW’s Harold C. Simmons Comprehensive Cancer Center.

Simon Rule, MD, discusses the potential for CAR T-cell therapy in treating patients with mantle cell lymphoma.

Sham Mailankody, MBBS, discusses research regarding the BCMA CAR T-cell therapy bb2121 in patients with relapsed/refractory multiple myeloma.

Miguel-Angel Perales, MD, discusses the use of CAR T-cell therapy in diffuse large B-cell lymphoma and transformed follicular lymphoma.

There are a number of policy changes that can drive change within the implementation of chimeric antigen receptor T-cell therapy, but further innovation is warranted to improve access, said John Sweetenham, MD, professor in the Department of Internal Medicine at UT Southwestern Medical Center and the Associate Director for Clinical Affairs at UTSW’s Harold C. Simmons Comprehensive Cancer Center.

Alfred L. Garfall, MD, MS, discusses the potential of CAR T-cell therapy in multiple myeloma.

Miguel-Angel Perales, MD, discusses replacing autologous stem cell transplant with CAR T-cell therapy in diffuse large B-cell lymphoma.

Jae H. Park, MD, discusses encouraging data with CAR T-cell therapy in acute lymphoblastic leukemia.

Saad Z. Usmani, MD, FACP, discusses the mechanisms of action of BCMA-targeted CAR T-cell therapy, bispecific monoclonal antibodies, and antibody-drug conjugates in multiple myeloma.

Agnieszka Janus, MD, PhD, discusses the efficacy and safety of moxetumomab pasudotox as a treatment option for patients with hairy cell leukemia. This agent was approved by the FDA in September 2018 for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy, including a purine nucleoside analog.

Alexander E. Perl, MD, MS, discusses the challenges of using immunotherapy with antibody-drug conjugates, bispecific T-cell engagers, and CAR T-cell therapies in acute myeloid leukemia.

Tanya Siddiqi, MD, discusses the rationale for the phase I/II TRANSCEND CLL 004 trial investigating the use of the CAR T-cell therapy lisocabtagene maraleucel in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

William G. Wierda, MD, PhD, discusses the use of CD19-targeted CAR T-cell therapy in the treatment of patients with chronic lymphocytic leukemia.

Anthony R. Mato, MD, MSCE, discusses where CAR T cell-therapy will fit into the treatment paradigm of chronic lymphocytic leukemia.

David E. Avigan, MD, professor of medicine, Harvard Medical School, and active staff, Hematology-Oncology, Beth Israel Deaconess Medical Center, discusses BCMA-targeted CAR T-cell therapy in multiple myeloma.

Nirali N. Shah, MD, MHSc, discusses the use of CAR T-cell therapy in pediatric patients with acute lymphocytic leukemia.

John F. DiPersio, MD, PhD, discusses the current state of CAR T-cell therapy, dual affinity re-targeting, bi-specific T-cell engagers, and antibody-drug conjugates for acute myeloid leukemia treatment.

Joshua P. Sasine, MD, PhD, discusses the challenges in predicting a patient’s individual benefit with CAR T-cell therapy in hematologic malignancies.

Nina Chavez, MBA, FACMPE, chief operating officer, New Mexico Oncology Hematology Consultants, Ltd., explains how expensive therapies like chimeric antigen receptor (CAR) T-cell therapy are creating reimbursement challenges.

This week, the top managed care news included Medicare cuts hospital payments over readmissions; a second-generation chimeric antigen receptor T-cell therapy shows promise; a diabetes drug is approved to prevent kidney failure for the first time.

Eduardo Sotomayor, MD, professor of medicine, Department of Hematology and Oncology, and director, GW Cancer Center, discusses the durability of CAR T cells, as well as ways to combat immune escape mechanisms in hematologic malignancies.

Raja Mudad, MD, FACP, discusses the RELAY trial and using doublet therapy to treat EGFR-mutant non–small cell lung cancer.

David E. Avigan, MD, discusses research surrounding CAR T-cell therapy in lymphoproliferative diseases.

Noelle Frey, MD, MSCE, discusses the use of CAR T-cell therapy in acute lymphocytic leukemia.

Wayne A. Marasco, MD, PhD, discusses ways CAR T cells are being engineered to avoid on-target adverse events in solid tumors.

Bijal D. Shah, MD, associate professor, Department of Malignant Hematology, Moffitt Cancer Center, discusses the use of CAR T-cell therapy in patients with pediatric acute lymphoblastic leukemia (ALL).

Eduardo Sotomayor, MD, professor of medicine, Department of Hematology and Oncology, and director, GW Cancer Center, discusses differences between FDA-approved CAR T-cell therapies.

Michael Wang, MD, discusses CAR T-cell therapy and triple-resistance in mantle cell lymphoma.

The only thing that should matter in these patients is their genetic code, but often it’s your zip code that really restrains your ability to access the healthcare you deserve, explained Ahmar Zaidi, MD, pediatric hematologist-oncologist, Comprehensive Sickle Cell Center, Children's Hospital of Michigan, when discussing the possibility of a gene therapy for sickle cell.